See more : Carpenter Tan Holdings Limited (0837.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Immunome, Inc. (IMNM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immunome, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bizmates, Inc. (9345.T) Income Statement Analysis – Financial Results
- MultiSensor AI Holdings, Inc. (MSAI) Income Statement Analysis – Financial Results
- CHC Group LLC (CHHCF) Income Statement Analysis – Financial Results
- Sirca Paints India Limited (SIRCA.NS) Income Statement Analysis – Financial Results
- Hangzhou Kaierda Robot Technology Co.,Ltd (688255.SS) Income Statement Analysis – Financial Results
Immunome, Inc. (IMNM)
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 14.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 22.93M | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| Gross Profit | -8.91M | -631.00K | -755.00K | -755.00K | -615.00K | -521.00K |
| Gross Profit Ratio | -63.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.80M | 23.27M | 14.11M | 7.49M | 8.82M | 6.88M |
| General & Administrative | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Other Expenses | 0.00 | 0.00 | 503.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 122.82M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Cost & Expenses | 123.55M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Interest Income | 2.72M | 5.00K | 10.00K | 1.00K | 10.00K | 39.00K |
| Interest Expense | 0.00 | 5.00K | 10.00K | 38.00K | 106.00K | 141.00K |
| Depreciation & Amortization | 728.00K | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| EBITDA | -28.27M | -36.27M | -23.95M | -17.04M | -9.72M | -7.18M |
| EBITDA Ratio | -201.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.53M | -36.90M | -25.20M | -12.26M | -10.35M | -7.74M |
| Operating Income Ratio | -781.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.72M | 5.00K | 493.00K | -5.58M | -96.00K | -102.00K |
| Income Before Tax | -106.81M | -36.90M | -24.71M | -17.84M | -10.44M | -7.85M |
| Income Before Tax Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 617.00K | -242.00K | -717.00K | 106.00K | 39.00K |
| Net Income | -106.81M | -37.51M | -24.47M | -17.12M | -10.55M | -7.85M |
| Net Income Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| EPS Diluted | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| Weighted Avg Shares Out | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
| Weighted Avg Shares Out (Dil) | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
IMNM Stock: The Covid Treatment News That Has Immunome Soaring Today
IMNM stock is having a great day today. The company is preparing to move forward with expedited testing for its delta variant treatment.
Immunome Stock Jumps As COVID-19 Antibody Shows Preclinical Neutralizing Activity Against Delta Variant
Immunome Inc (NASDAQ: IMNM) has announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against COVI-19 Delta variant in pre-clinical pseudovirus testing. Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.
IMNM Stock Increases Over 35% Pre-Market: Why It Happened
The stock price of Immunome Inc (NASDAQ: IMNM) increased by over 35% pre-market. This is why it happened.
Immunome Secures Additional $4.3M Funding From DoD To Develop COVID-19 Antibody Cocktail
Immunome Inc (NASDAQ: IMNM) has secured additional funding of $4.3 million from the Department of Defense (DoD) for the development of an antibody cocktail (IMM-BCP-01) to combat SARS-CoV-2 and its variants. The additional capital comes less than a year after an initial DOD...
Immunome Reports First Quarter 2021 Financial Results
EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports First Quarter 2021 Financial Results
IMNM Stock: Over 10% Increase Pre-Market Explanation
The stock price of Immunome Inc (NASDAQ: IMNM) increased by over 10% pre-market. This is why it happened.
Immunome Raises $27M Via Private Equity Placement At 9%
In addition to encouraging preclinical data from the COVID-19 antibody cocktail announced today, Immunome Inc (NASDAQ: IMNM) has entered into a private placement agreement of approximately $27 million with the sale of 1 million units at $27 per unit. The offer price is at a 9% discount...
Immunome's Stock Jumps On Its Antibody Cocktail Neutralizing Multiple COVID-19 Variants In Animal Studies
Immunome Inc (NASDAQ: IMNM) has announced antibody selection for its IMM-BCP-01 antibody cocktail and shared preclinical data showing that IMM-BCP-01 is effective against the current SARS-CoV-2 and its variants. In Syrian hamsters infected with live SARS-CoV-2 virus, IMM-BCP-01 reduced lung viral load as a...
Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
EXTON, Pa.--(BUSINESS WIRE)--Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Heads Toward IND Filing
Immunome Announces $27 Million Private Placement
EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces $27 Million Private Placement
Source: https://incomestatements.info
Category: Stock Reports